Clinical Trial Update: A Phase II Study of Sintilimab Combined With Anlotinib in Treatment of ED-SCLC [Phase 2]

View source ↗

Summary

Phase II study evaluating sintilimab plus anlotinib in extensive-stage small cell lung cancer is underway (details currently unknown).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• Sintilimab (sintilimab)

Snippet

Sponsor: Zhejiang Cancer Hospital | Conditions: Small Cell Lung Cancer Extensive Stage | Phase 2 | Status: UNKNOWN